Predict your next investment

Victor company logo
Corporation
INTERNET | eCommerce / Travel (internet)
flyvictor.com

See what CB Insights has to offer

Founded Year

2010

Stage

Series B - II | Alive

Total Raised

$61.26M

Last Raised

$18M | 4 yrs ago

Revenue

$0000 

About Victor

Victor is an on-demand B2C jet charter platform specializing in the private aviation industry. Launched in 2011, the company offers a fully-transparent, subscription-free, globally 'on-demand' marketplace allowing members to swiftly check pricing options and aircraft specifics before booking the flights they need. Victor's unique combination of smart technology and exceptional 'high touch' customer service, means that its B2C customers – with access to thousands of aircraft via a global network of over 200 partner operators – are always connected and in control.

Victor Headquarter Location

60 Sloane Avenue

London, England, SW3 3XB,

United Kingdom

+44 02073848550

Latest Victor News

jCyte Announces Appointment of Victor Chao as Vice President of CMC Operations

Sep 9, 2021

September 09, 2021 09:30 AM Eastern Daylight Time NEWPORT BEACH, Calif.--( BUSINESS WIRE )-- jCyte, Inc. , a private biotechnology company dedicated to improving the lives of patients with retinal degenerative diseases, announced the continued expansion of the Company’s leadership team with the appointment of Victor Chao as Vice President of Chemistry, Manufacturing and Controls (CMC) Operations. Mr. Chao joins jCyte with over 25 years of industry experience across numerous corporate operational leadership roles in CMC operations, cGMP global manufacturing, distribution, and supply chain management for multiple blockbuster biological therapies and commercial and corporate operations for ophthalmology prescription medicines, surgical devices, and biosimilars. Mr. Chao joins jCyte from Santen Pharmaceuticals where he served as the Head of Commercial Operations for North and Latin America, responsible for Commercial Alliances and Partnerships, Market Access and Reimbursement, Trade and Distribution, and Launch Readiness for all of Santen’s ophthalmology pharmaceutical products and surgical devices. Prior to Santen, Mr. Chao was with McKesson Specialty Health as the Senior Director of Multisource Products for six years where he led, scaled, and launched numerous process initiatives and products and was responsible for McKesson’s $300M generics and biosimilars business. Before joining McKesson, Mr. Chao spent eight years at Bayer Healthcare Pharmaceuticals in leadership roles responsible for CMC operations, process engineering, and global supply chain management for their multi-billion-dollar products Betaseron® and Kogenate® across multiple manufacturing sites within the United States and Europe. Importantly, Mr. Chao helped design and implement the purification process for late-stage clinical trial production of Kogenate PF® and, following Bayer’s acquisition of its key growth asset Betaseron® from Novartis, he rebuilt engineering teams, managed a cross-functional team of over 250 people to execute an extensive purification and fill/finish facility upgrade project, and led the transfer of the manufacturing process to another facility in Europe. Victor holds a BS in chemical engineering from Brigham Young University and earned his MBA from The Wharton School with a dual major in strategy and entrepreneurship. “I am excited to welcome Victor to the jCyte senior leadership team as we continue to expand the Company’s corporate infrastructure to manufacture jCell at commercial scale, complete our pivotal Phase 3 trial for our lead indication and prepare to deliver jCell to patients with significant unmet medical needs,” said Dr. Shannon Blalock, Chief Executive Officer. “Victor brings a unique breadth and depth of CMC and corporate operational experience to jCyte at this critical juncture in the Company’s evolution as we rapidly advance our jCell platform technology to Phase 3 trials for RP and other retinal degenerative disorders and prepare for global commercialization. We look forward to leveraging Victor’s highly diversified experience and proven track record of successfully leading and supporting the manufacture of multiple novel multi-billion-dollar biological products, launching the first set of blockbuster biosimilar therapies, filgrastim and infliximab, in the US, and leading North and Latin American commercial operations for a Top 4 global ophthalmology pharmaceutical company who is the market leader throughout most of Asia. His addition to the team will help ensure we get our transformative cell therapy to the millions of patients around the world who currently have no treatment options as quickly as possible.” jCell is a first-in-class investigational treatment for RP which has received FDA Regenerative Medicine Advanced Therapy (RMAT) designation. In addition to RMAT designation, jCell has received Orphan Drug designation from the FDA and the European Medicines Agency (EMA). About jCyte, Inc. jCyte, Inc. is a late-stage clinical phase biotech company focused on developing its first-in-class regenerative cell therapy, jCell, for retinitis pigmentosa (RP) and other retinal degenerative disorders. The treatment is minimally invasive and given as an intravitreal injection. There are currently no FDA approved therapies for RP. The Company is pioneering a new era of regenerative therapies to address the significant unmet medical needs of patients suffering from a broad set of retinal degenerative diseases. For more information, visit www.jcyte.com . Contacts

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Victor

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Victor is included in 2 Expert Collections, including On-Demand.

O

On-Demand

1,239 items

T

Travel Technology (Travel Tech)

2,080 items

The travel tech collection includes companies offering tech-enabled services and products for tourists and travel players (hotels, airlines, airports, cruises, etc.). It excludes financial services and micro-mobility solutions.

Victor Patents

Victor has filed 569 patents.

The 3 most popular patent topics include:

  • Industrial gases
  • Welding
  • Arc welding
patents chart

Application Date

Grant Date

Title

Related Topics

Status

8/26/2020

9/28/2021

Team sports, Solid mechanics, Racquet sports, Mechanical engineering, Mechanics

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

8/26/2020

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

9/28/2021

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Team sports, Solid mechanics, Racquet sports, Mechanical engineering, Mechanics

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Victor Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Victor Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.